6.53

0.00% 0.00

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $6.53, with a volume of 114.31K. It is up +0.00% in the last 24 hours and up +43.20% over the past month. Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Previous Close:

$6.53

Open:

$6.46

24h Volume:

114.31K

Relative Volume:

0.08

Market Cap:

$689.13M

Revenue:

Net Income/Loss:

$-57.39M

P/E Ratio:

-4.4428

EPS:

-1.4698

Net Cash Flow:

$-45.79M

1W Performance:

+7.58%

1M Performance:

+43.20%

6M Performance:

+260.77%

1Y Performance:

+2,091%

1-Day Range:

$6.40

$6.65

1-Week Range:

$5.68

$6.735

52-Week Range:

$0.243

$7.51

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (623)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2026-03-19

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD vs MOBBW, PSNYW, GOODO, SHMD, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	2.07	2.75B	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	5.20	482.87M	2.07B	-1.42B	-1.37B	-0.6765
GOODO Gladstone Commercial Corporation	19.85	372.90M	0	0	0	0.00
SHMD Schmid Group N V	5.94	366.98M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	42.86	0	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Resumed	Leerink Partners	Outperform
Dec-22-25	Initiated	Jefferies	Buy
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

Mar 26, 2026

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com

Mar 26, 2026

Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget

Mar 26, 2026

Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com India

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com

Mar 25, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat

Mar 25, 2026

Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN

Mar 25, 2026

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey

Mar 25, 2026

Mar 24, 2026

Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - GuruFocus

Mar 24, 2026

Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha

Mar 24, 2026

Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo

Mar 24, 2026

Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat

Mar 24, 2026

Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus

Mar 24, 2026

Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com

Mar 24, 2026

Mar 22, 2026

Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart

Mar 21, 2026

Mar 20, 2026

Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks

Mar 20, 2026

Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks

Mar 20, 2026

Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan

Mar 20, 2026

Relmada Therapeutics price target raised to $19 from $10 at Mizuho - TipRanks

Mar 20, 2026

RLMD: Mizuho Analyst Raises Price Target to $19, Maintains Outpe - GuruFocus

Mar 20, 2026

VR Adviser Adds Over 1 Million Savara Shares - AOL.com

Mar 20, 2026

Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00 - MarketBeat

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com

Mar 20, 2026

Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 20, 2026